Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Selected readings
Vane JR (1971) Inhibition of prostaglandin synthesis as a mechanism of action for the aspirin-like drugs. Nature 231: 232–235
Xie W, Chipman JG, Robertson DL, Erikson RL, Simmons DL (1991) Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci USA 88: 2692–2696
Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal NM, Stenso WF et al (2000) Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. J Am Med Assoc 284: 1247–1255
Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC et al; VIGOR Study Group (2000) Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Eng J Med 343: 1520–1528
Chandrasekharan NV, Dai H, Roos KL, Evanson NK, Tomsik J, Elton TS, Simmons DL (2002) COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci USA 99: 13926–13931
References
Vane JR, Botting RM (1996) The history of anti-inflammatory drugs and their mode of action. In: N Bazan, J Botting, J Vane (eds): New Targets in Inflammation Inhibitors of COX-2 or Adhesion Molecules. Kluwer Academic Publishers and William Harvey Press, London: 1–12
Dreser H (1899) Pharmacologisches über Aspirin (Acetylsalicylsäure). Pflügers Arch 76: 306–318
Douthwaite A, Lintott CA (1938) Gastroscopic observations of the effect of aspirin and certain other substances on the stomach. Lancet 2: 1222
Vane JR (1971) Inhibition of prostaglandin synthesis as a mechanism of action for the aspirin-like drugs. Nature 231: 232–235
Vane JR, Botting RM (1992) The Prostaglandins. In: JR Vane, RM Botting (eds): Aspirin and other Salicylates. Chapman & Hall, London, 17–34
Warner TD, Guiliano F, Vojnovic I, Bukasa A, Mitchell JA, Vane JR (1999) Nonsteroid drug selectivities for cyclooxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci USA: 96: 7563–7568
Carr DP, Henn R, Green JR, Böttcher I (1986) Comparison of the systemic inhibition of thromboxane synthesis, anti-inflammatory activity and gastro-intestinal toxicity of non-steroidal anti-inflammatory drugs in the rat. Agents and Actions 19: 374–375
Flower RJ, Vane JR (1972) Inhibition of prostaglandin synthetase in brain explains the antipyretic activity of paracetamol (4-acetamidophenol). Nature 240: 410–411
Morrison AR, Moritz H, Needleman P (1978) Mechanism of enhanced renal biosynthesis of prostaglandins in ureter obstruction. Role of de novo protein biosynthesis. J Biol Chem 253: 8210–8212
Kawakami M, Ishibashi S, Ogawa H, Murase T, Takaku F, Shibata S (1986) Cachectin/TNF as well as interleukin-1 induces prostacyclin synthesis in cultured vascular cells. Biochem Biophys Res Commun 141: 482–487
Honda A, Raz A, Needleman P (1990) Induction of cyclo-oxygenase synthesis in human promyelocytic leukemia (HL-60) cells during monocytic or granulocytic differentiation. Biochem J 272: 259–262
Fu J-Y, Masferrer JL, Seibert K, Needleman P (1990) The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes. J Biol Chem 265: 16737–16740
Masferrer JL, Zweifel BS, Seibert K, Needleman P (1990) Selective regulation of cellular cyclooxygenase by dexamethasone and endotoxin in mice. J Clin Invest 86: 1375–1379
Masferrer JL, Zweifel BS, Seibert K, Needleman P (1990) Selective regulation of cellular cyclooxygenase by dexamethasone and endotoxin in mice. J Clin Invest 86: 1375–1379
Simmons DL, Levy DB, Yannoni Y, Erikson RL (1989) Identification of a phorbol ester-repressible v-srcinducible gene. Proc Natl Acad Sci USA 86: 1178–1182
Xie W, Chipman JG, Robertson DL, Erikson RL, Simmons DL (1991) Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci USA 88: 2692–2696
Kujubu DA, Fletcher BS, Varnum BC, Lim RW, Herschman HR (1991) TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J Biol Chem 266: 12866–12872
Simmonds DL, Xie W, Chipman J, Evett G (1991) Multiple cyclooxygenases: cloning of a mitogen-inducible form. In: M Bailey (ed): Prostaglandins, Leukotrienes, Lipoxins and PAF. Plenum Press, London, 67–68
McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Fitzgerald GA (1999) Systemic biosynthesis of prostacyclin by cyclooxygenase (COX-2): The human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci USA: 96: 272–277
Willoughby DA, Tomlinson A, Gilroy D, Willis D (1996) Inducible enzymes with special reference to the inflammatory response. In: JR Vane, JH Botting, RM Botting (eds): Improved Non-steroid Anti-inflammatory Drugs. COX-2 Enzyme Inhibitors. Kluwer and William Harvey Press, London, 67–83
Sano H, Hla T, Maier JA, Crofford LJ, Case JP, Maciag T, Wilder RL (1992) In vivo cylooxygenase expression in synovial tissues of patients wth rheumatoid arthritis and osteoarthritis and rats with adjuvant and streptococcal cell wall arthritis. J Clin Invest 89: 97–108
Patrignani P, Panara MR, Greco A, Fusco O, Natoli C, Iacobelli S, Cipollone F, Ganci A, Creminon C, Maclouf J et al (1994) Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases. J Pharmacol Exp Ther 271: 1705–1710
Picot D, Loll PJ, Garavito RM (1994) The x-ray crystal structure of the membrane protein prostaglandin H2 synthase-1. Nature 367: 243–249
Luong C, Miller A, Barnett J, Chow J, Ramesha C, Browner MF (1996) Flexibility of the NSAID binding site in the structure of human cyclooxygenase-2. Nat Struct Biol 3: 927–933
Wong E, Bayly C, Waterman HL, Reindeau D, Mancini JA (1997) Conversion of prostaglandin G/H synthase-1 into an enzyme sensitive to PGHS-2-selective inhibitors by a double His513 to Arg and Ile523 to Val mutation. J Biol Chem 272: 9280–9286
Browner MF (1998) The structure of human COX-2 and selective inhibitors. In: J Vane, J Botting J (eds): Selective COX-2 Inhibitors. Pharmacology, Clinical Effects and Therapeutic Potential. Kluwer and William Harvey Press, London, 19–26
Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal NM, Stenson WF et al (2000) Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomised controlled trial. Celecoxib Long-term Arthritis Safety Study. J Am Med Assoc 284: 1247–1255
Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC et al; VIGOR Study Group (2000) Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 343: 1520–1528
Giovannucci E, Egan KM, Hunter DJ (1995) Aspirin and the risk of colorectal cancer. N Engl J Med 333: 609–614
Greenberg ER, Baron JA, Freeman DH, Mandel JS, Haile R (1993) Reduced risk of large bowel adenomas among aspirin users. The Polyp Prevention Study Group. J Natl Cancer Inst 85: 912–916
Thun MJ, Namboodiri MM, Heath CWJ (1991) Aspirin use and reduced risk of coloc cancer. N Engl J Med 325: 1593–1596
Thun MJ, Namboodiri MM, Calle EE, Flandes WD, Heath CW (1993) Aspirin use and risk of fatal cancer. Cancer Res 53: 1322–1327
Peleg II, Maibach HT, Brown SH, Wilcox CM (1994) Aspirin and nonsteroidal antiinflammatory drug use and the risk of subsequent colorectal cancer. Arch Int Med 154: 394–399
Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Ascherio A, Willett WC (1994) Aspirin use and the risk of colorectal cancer and adenoma in male health professionals. Ann Intern Med 121: 241–246
Eberhart CE, Coffey RJ, Radhika A (1994) Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107:1183–1188
Giardello FM, Hamilton SR, Krush AJ (1993) Treatment of colonic and rectal carcinomas with sulindac in familial adenomatous polyposis. N Engl J Med 328: 1313–1316
Waddell WR, Loughry RW (1983) Sulindac for polyposis of the colon. J Surg Oncol 24: 83–87
Waddell WR, Gasner GF, Cerise EJ, Loughry RW (1989) Sulindac for polyposis of the colon. Am J Surg 157:175–178
Reddy BS, Rao CV, Rivenson A, Kellof G (1993) Inhibitor effect of aspirin on azoxymethane-induced colon carcinogenesis in F344 rats. Carcinogenesis 14: 1493–1497
Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB (2000) The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342: 1946–1952
Ristimaki A, Narko K, Nieminen, Saukkonen K (2001) Role of cyclooxygenase-2 in carcinogenesis other than colorectal cancer. In: JR Vane, RM Botting (eds): Therapeutic Roles of Selective COX-2 Inhibitors. William Harvey Press, London, 418–441
Bennett PR, Elder MG (1992) The mechanisms of preterm labour: common genital tract pathogens do not metabolise arachidonic acid to prostaglandins or other eicosanoids. Am J Obstet Gynecol 166: 1541–1545
Sawdy R, Slater D, Fisk N, Edmonds DK, Bennett P (1997) Use of a cyclo-oxygenase type-2-selective nonsteroidal anti-inflammatory agent to prevent preterm delivery. Lancet 350: 265–266
Peruzzi L, Gianoglio B, Porcellini MG, Coppo R (1999) Neonatal end-stage renal failure associated with maternal ingestion of cyclo-oxygenase-type-1 selective inhibitor nimesulide as tocolytic. Lancet 354: 1615
Allport V, Bennett P (2001) Cyclooxygenase enzymes and human labour. In: JR Vane, RM Botting (eds): Therapeutic Roles of Selective COX-2 Inhibitors. William Harvey Press, London, 252–273
Stewart WF, Kawas C, Corrada M, Metter EJ (1997) Risk of Alzheimer’s disease and duration of NSAID use. Neurology 48: 626–632
Pasinetti GM, Aisen PS (1998) Cyclooxygenase-2 expression is increased in frontal cortex of Alzheimer’s disease brain. Neuroscience 87: 319–324
Lim GP, Yang F, Chu T, Chen P, Beech W, Teter B, Tran T, Ubeda O, Ashe KH, Frautschy SA et al (2000) Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer’s disease. J Neurosci 20: 5709–5714
McGeer PL (2000) Cyclo-oxygenase-2 inhibitors: rationale and therapeutic potential for Alzheimer’s disease. Drugs Aging 17: 1–11
Sainati SM, Ingram DM, Talwalker S, Geis GS (2000) Results of a double-blind, randomized, placebo-controlled study of celecoxib in the treatment of progression of Alzheimer’s disease. Abstracts of the Sixth International Stockholm/Springgfield Symposium on Advances in Alzheimer Therapy. April 5–8, 2000
Weggen S, Eriksen JL, Das P, Sagi SA, Wang R, Pietrzik CU, Findlay KA, Smith TE, Murphy MP, Bulter T et al (2001) A subset of NSAIDs lower amyloidogenic Aß42 independently of cyclooxygenase activity. Nature 414: 212–216
Zandi PP, Anthony JC, Hayden KM, Mehta K, Mayer L, Breitner JC (2002) Reduced incidence of AD with NSAID but not H2 receptor antagonists. The Cache County study. Neurology 59: 880–886
Chandrasekharan NV, Dai H, Roos KL, Evanson NK, Tomsik J, Elton TS, Simmons DL (2002) COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci USA 99: 13926–13931
Simmons DL, Botting RM, Robertson PM, Madsen ML, Vane JR (1999) Induction of an acetaminophen-sensitive cyclooxygenase with reduced sensitivity to nonsteroid antiinflammatory drugs. Proc Natl Acad Sci USA 96: 3275–3280
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2005 Birkhäuser Verlag
About this chapter
Cite this chapter
Botting, R.M., Botting, J.H. (2005). Non-steroidal anti-inflammatory drugs. In: Nijkamp, F.P., Parnham, M.J. (eds) Principles of Immunopharmacology. Birkhäuser Basel. https://doi.org/10.1007/3-7643-7408-X_27
Download citation
DOI: https://doi.org/10.1007/3-7643-7408-X_27
Publisher Name: Birkhäuser Basel
Print ISBN: 978-3-7643-5804-4
Online ISBN: 978-3-7643-7408-2
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)